Table 3 Univariate analysis of prognostic factors for patients with metastatic lymph node positive gastric cancer
From: Metastatic lymph node in gastric cancer; Is it a real distant metastasis?
| Â | 1 YSR | 3 YSR | Median OS (95% C.Ia) months | H.R (95% C.Ia) | P value |
|---|---|---|---|---|---|
Age | Â | Â | Â | Â | 0.461 |
   < 65 | 82.1% | 42.9% | 25.6 (11.0 - 40.2) | 1.0 |  |
   > 65 | 65.2% | 39.1% | 19.2 (11.8 - 26.6) | 1.232 (0.707 - 2.145) |  |
Sex | Â | Â | Â | Â | 0.204 |
   Male | 77.4% | 47.2% | 31.0 (15.2 - 46.9) | 1.0 |  |
   female | 76.9% | 30.8% | 16.1 (11.9 - 20.2) | 1.416 (0.828 - 2.421) |  |
ECOG P.S | Â | Â | Â | Â | 0.464 |
   0 | 80.0% | 40.0% | 20.9 (0.0 - 49.6) | 1.0 |  |
   1 | 76.5% | 42.7% | 21.0 (12.2 - 29.8) | 0.776 (0.381 - 1.582) |  |
   2 | 100% | 0% | 13.9 (13.9 - 13.9) | 2.304 (0.285 - 18.624) |  |
Primary site | Â | Â | Â | Â | 0.012 |
   Low & mid-body | 82.4% | 45.6% | 26.5 (10.6 - 42.3) | 1.0 |  |
   High body & whole stomach | 45.5% | 18.2% | 9.2 (0.0 - 19.7) | 2.417 (1.216 - 4.806) |  |
Bormann type | Â | Â | Â | Â | 0.031 |
   I |  |  |  |  |  |
   II | 82.4% | 58.8% | 52.9 | 1.0 |  |
   III | 78.9% | 42.3% | 21.7 (7.8 - 35.6) | 1.845 (0.895 - 3.803) |  |
   IV | 60.0% | 10.0% | 13.0 (9.8 - 16.1) | 3.521 (1.379 - 8.991) |  |
Lauren classification | Â | Â | Â | Â | 0.207 |
   Intestinal | 75.0% | 30.0% | 16.3 (15.7 - 16.8) | 1.0 |  |
   Diffuse | 78.9% | 57.9% | 38.9 (31.0 - 46.8) | 0.659 (0.344 - 1.233) |  |
   Mixed | 75.0% | 25.0% | 14.1 (0.0 - 29.0) | 0.920 (0.266 - 3.181) |  |
   Unknown | 76.5% | 23.5% | 15.5 (12.3 - 18.7) | 1.274 (0.622 - 2.610) |  |
Histological grade | Â | Â | Â | Â | 0.954 |
   Well to moderate | 86.9% | 39.1% | 20.8 (16.4 - 25.2) | 1.0 |  |
   Poor to undifferentiated | 73.2% | 42.9% | 21.7 (5.9 - 37.5) | 1.017 (0.578 - 1.787) |  |
Type of gastrectomy | Â | Â | Â | Â | 0.014 |
   Total gastrectomy | 70.3% | 29.3% | 17.1 (13.2 - 21.1) | 1.913 (1.143 - 3.203) |  |
   Subtotal gastrectomy | 83.3% | 52.4% | 36.6 (13.9 - 59.3) | 1.0 |  |
Extent of surgery | Â | Â | Â | Â | 0.006 |
   None | 81.4% | 49.2% | 34.9 (16.4 - 53.4) | 1.0 |  |
   Resection of spleen | 60.0% | 20.0% | 13.0 (9.7 - 16.2) | 2.937 (1.604 - 5.337) |  |
   Resection of distal pancreas | 66.7% | 33.3% | 16.1 (0.0 - 34.9) | 1.353 (0.327 - 5.606) |  |
   Resection of spleen, pancreas | 100% | 0% | 18.1 | 1.953 (0.466 - 8.195) |  |
T staging | Â | Â | Â | Â | 0.116 |
   T1 |  |  |  |  |  |
   T2 | 80.0% | 56.7% | 38.9 (3.9 - 73.9) | 1.0 |  |
   T3 | 75.6% | 31.7% | 19.1 (14.3 - 23.8) | 1.797 (1.010 - 3.198) |  |
   T4 | 75.0% | 37.5% | 16.1 (0.0 - 32.6) | 1.861 (0.775 - 4.468) |  |
N staging | Â | Â | Â | Â | < 0.001 |
   N1 | 92.9% | 71.4% | 59.6 (32.9 - 86.3) | 1.0 |  |
   N2 | 88.0% | 60.0% | 52.2 (35.4 - 69.0) | 1.121 (0.470 - 2.674) |  |
   N3 | 65.0% | 20.0% | 14.8 (9.7 - 19.9) | 3.870 (1.770 - 8.463) |  |
No. of dissected LNs | Â | Â | Â | Â | 0.810 |
   < 40 | 75.8% | 42.4% | 25.6 (4.7 - 46.6) | 1.065 (0.637 - 1.781) |  |
   > 40 | 78.3% | 41.3% | 20.8 (11.1 - 30.5) | 1.0 |  |
Metastatic lymph node station | Â | Â | Â | Â | 0.230 |
   #12 | 76.8% | 39.1% | 20.8 (12.2 - 29.4) | 1.0 |  |
   #13 | 80.0% | 60.0% | 47.7 (0.4 - 95.0) | 0.596 (0.256 - 1.388) |  |
Post-operative treatment | Â | Â | Â | Â | 0.209 |
   None | 57.1% | 38.1% | 14.8 (5.4 - 24.1) | 1.0 |  |
   Chemotherapy | 83.3% | 37.5% | 21.0 (11.6 - 30.5) | 0.869 (0.484 - 1.562) |  |
   Chemo-radiation | 100% | 75.0% |  | 0.266 (0.078 - 0.916) |  |
   Unknown | 50.0% | 0% | 11.6 | 1.020 (0.234 - 4.444) |  |
Lymph node dissection | Â | Â | Â | Â | 0.357 |
   D2 | 76.3% | 43.4% | 21.0 (8.3 - 33.8) | 1.0 |  |
   D3 | 100% | 0% | 18.1 (15.2 - 21.0) | 1.739 (0.536 - 5.643) |  |